Global Diabetes Care Drugs Market Size, Share, Opportunities, And Trends By Condition (Diabetes Type 1, Diabetes Type 2), By Drug Class (Insulin (Rapid Acting, Short-Acting, Long Acting, Others), Sulfonylureas, Meglinitides, Thiazolidinedione, Others), By Delivery Method (Vials, Pens, Tablets), By End-User (Hospitals and Clinics, Household), And By Geography - Forecasts from 2025 to 2030

Diabetes Care Drugs Market Size:

The Global Diabetes Care Drugs Market is expected to grow from USD 87.784 billion in 2025 to USD 109.119 billion in 2030, at a CAGR of 4.45%.

Diabetes Care Drugs Market Trends:

• The rising prevalence of type 1 in children and type 2 diabetes in adults is causing a surge in demand.

According to WHO, diabetes is a chronic disease that is caused by a high level of glucose present in the blood. It can lead to severe damage to organs such as the heart, blood vessels, and kidneys, among others. Diabetes type 2 is considered the most common type of diabetes and affects adults when the body becomes resistant to insulin.

On the other hand, type 1 diabetes is dependent on insulin and is caused when the pancreas produces very little insulin. The number of individuals suffering from diabetes rose from 108 million to 422 million in 2014. Moreover, the prevalence of diabetes in individuals over 18 years, which was previously found to be 4.7% in 1980, has surged to 8.5% in 2014.

In addition, diabetes can be treated if a healthy diet is followed and a good amount of exercise and strict recommendation from the doctor is followed. On the other hand, persons suffering from diabetes are actively demanding diabetes care drugs to keep their condition in check, and this is leading to market growth.

Diabetes Care Drugs Market Growth Drivers:

• A growing proportion of the geriatric population is driving the market growth.

One of the major factors of the rise in demand for diabetic care drugs from geriatric individuals is the fact that during older age, the immune system and the endocrine system, among the other functions of the body, are not up to their full potential, which makes pancreas little weaker and thus making them prone to diabetes. Therefore, this is causing the elderly population to demand diabetic drugs.

Diabetes Care Drugs Market Key Players - Product Offerings:

• Product offerings, acquisitions, and launches by Major Market Players in the diabetes care drugs market space

The involvement and participation of the market player are increasing to cater to the demand of the end-user more effectively. They are bringing advancement and enhancements by the launch of new products and partnership agreements with better compositions, which are more effective, thus contributing to improving their market position and bolstering the market growth further.

Some examples of product launches and partnership agreements are as follows:

• In May 2022, the new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist MounjaroTM (tirzepatide) injection from Eli Lilly and Company was given FDA approval. It is indicated as a supplement to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro is not recommended for use in people with type 1 diabetes mellitus and has not been evaluated in individuals with a history of pancreatitis.
• In February 2022, Suganon® (evogliptin), a novel treatment for people with type 2 diabetes, was introduced in Latin America by Eurofarma. New DPP-4 enzyme inhibitor Suganon® (evogliptin) provides the advantages of simple administration and low possibility for drug interactions, delivering better convenience and safety for prescribers and type 2 diabetic patients.
• Recently in April 2020, Natco Pharma, which is a company dealing in the provision of different types of drugs and is based in India, announced that they had launched a new product under the brand name “Danpat.”The product is an affordable and low-cost copy of the drug called “Farxiga,” a drug by the company AstraZeneca. In addition, this drug, which has been launched, is lower in concentration than Farxiga and will be available in 5mg and 10mg.
• In January 2020, Eli Lilly and Company announced their latest triple combination drug called “Trijardy XR,” which consists of three diabetes type-2 medications. The tablet consists of “empagliflozin,” "linagliptin,” and an extended-release drug called “metformin hydrochloride” has been approved for usage by the U.S. Food and Drug Administration. It will be available in four different dosages and is indicated to be used once daily, together with a healthy and complete diet and exercise.
• In September 2019, a new medication called “Ryebelsus” (semaglitude), developed by the company Novo Nordisk, was approved by the U.S. Food and Drug Administration. The medication has been developed for the glucagon-like peptide (GLP-1) receptor protein treatment and is approved for use in the United States; that is the first oral drug. It can improve control over the blood sugar in adult patients suffering from type 2 diabetes and is a non-insulin type treatment.
• In December 2019, Mankind Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd. announced that they had entered into a partnership agreement to co-market the anti-diabetic drug called “remogliflozin etabonate” in India. Under this agreement, Mankind Pharma will market the drug under its trademark. On the other hand, Glenmark will contribute to the agreement by manufacturing and supplying the drug to the company.

Diabetes Care Drugs Market Geographical Outlook:

• The Asia Pacific region is poised to show a considerable growth rate over the forecast period owing to increasing healthcare sector spending, and the North American region is expected to hold a noteworthy share over the forecast period.

The North American region is expected to hold a noteworthy share over the forecast period owing to the fact that the healthcare sector in countries such as the US is well developed. In conjunction, there is a good number of investments in the R&D of better drugs and medicines in order to control diabetes type 2 effectively pharmaceutical companies.

The Asia Pacific region is poised to show a considerable growth rate over the forecast period, owing to the increasing number of efforts being made and the initiatives being taken by the government by pumping investments into the healthcare sector in order to promote the development of better drugs for diseases such as diabetes in India. In addition, there is increasing involvement of market players such as Mankind and Glenmark to manufacture and distribute diabetes-related drugs in countries such as India.

Diabetes Care Drugs Market Segmentation:

• By Condition
  • Diabetes Type 1
  • Diabetes Type 2
• By Drug Class
  • Insulin
    • Rapid Acting
    • Short-Acting
    • Long Acting
    • Others
  • Sulfonylureas
  • Meglitinides
  • Thiazolidinedione
  • Others
• By Delivery Method
  • Vials
  • Pens
  • Tablets
• By End-User
  • Hospitals and Clinics
  • Household
  • Ambulatory and Diagnostics Centers
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Other

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. DIABETES CARE DRUG MARKET BY CONDITION

5.1. Introduction

5.2. Diabetes Type 1

5.3. Diabetes Type 2

6. DIABETES CARE DRUG MARKET BY DRUG CLASS

6.1. Introduction

6.2. Insulin

6.2.1. Rapid Acting

6.2.2. Short-Acting

6.2.3. Long Acting

6.2.4. Others

6.3. Sulfonylureas

6.4. Meglitinides

6.5. Thiazolidinedione

6.6. Others

7. DIABETES CARE DRUG MARKET BY DELIVERY METHOD

7.1. Introduction

7.2. Vials

7.3. Pens

7.4. Tablets

8. DIABETES CARE DRUG MARKET BY END-USER

8.1. Introduction 

8.2. Hospitals and Clinics

8.3. Household

8.4. Ambulatory and Diagnostics Centers

9. DIABETES CARE DRUG MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. USA

9.2.2. Canada

9.2.3. Mexico

9.3. South America

9.3.1. Brazil

9.3.2. Argentina

9.3.3. Others

9.4. Europe

9.4.1. Germany

9.4.2. France

9.4.3. United Kingdom

9.4.4. Spain

9.4.5. Others

9.5. Middle East and Africa

9.5.1. Saudi Arabia

9.5.2. UAE

9.5.3. Others

9.6. Asia Pacific

9.6.1. China

9.6.2. India

9.6.3. Japan

9.6.4. South Korea

9.6.5. Indonesia

9.6.6. Thailand

9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. Novo Nordisk 

11.2. Eli Lilly 

11.3. Sanofi 

11.4. Merck & Co. 

11.5. AstraZeneca 

11.6. Boehringer Ingelheim 

11.7. Takeda Pharmaceutical 

11.8. Pfizer 

11.9. Johnson & Johnson 

11.10. Biocon 

11.11. Cipla 

11.12. Dr. Reddy’s Laboratories 

11.13. Lupin 

11.14. Sun Pharma

12. APPENDIX

12.1. Currency 

12.2. Assumptions

12.3. Base and Forecast Years Timeline

12.4. Key benefits for the stakeholders

12.5. Research Methodology 

12.6. Abbreviations 

Novo Nordisk

Eli Lilly

Sanofi

Merck & Co.

AstraZeneca

Boehringer Ingelheim

Takeda Pharmaceutical

Pfizer

Johnson & Johnson

Biocon

Cipla

Dr. Reddy’s Laboratories

Lupin

Sun Pharma